Tel Aviv University

Brainstorm Cell Therapeutics Ltd.

Other

Yeda Research and Develpment & Co. Ltd

Technion Research & Development Foundation Ltd

Brainstorm Ceil Therapeutics Ltd.

Eggxyt Ltd

Offen, Daniel

Daniel Offen

Eldad Melamed

Merav Bahat-Stromza

Avinoam Kadouri

Ofer Sadan

Avihay Bar-Ilan

Nirit Lev

Javier Ganz

Daphne Atlas

Moshe Portnoy

Gerardo Zelmar Lederkremer

Julia Leitman

Israel Aharony

Hagit Eiger

Nisim Perets

Michal Dadon-Nachum

Tali Ben-Zur

David Yaffe

Shulamit Levenberg

Sandu Pitaru

Shaowei Guo

Chen Benkler

Henn Benkler

The present invention provides pharmaceutical compositions comprising membrane vesicles, including extracellular vesicles including those referred to as exosomes, loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor. Methods of treating neurological diseases, disorders or conditions using the extracellular vesicles are provided. Isolated extracellular vesicles loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor are provided as well.

Vesicles comprising a PTEN inhibitor and uses of same

An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.

Mesenchymal stem cells for the treatment of CNS diseases

A method of treating a neurological disease (such as autism) in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of microparticles derived from mesenchymal stem cells.

Mesenchymal cell-derived exosomes to treat neurological disorders

Compounds represented by Formula I are disclosed herein,  wherein R, Ra and R-Rare as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.

Isolated cells and populations comprising same for the treatment of CNS diseases

An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.

Genetically modified muscle cells which express neurotrophic factors

Compounds represented by Formula I are disclosed herein, wherein R, Ra and R-Rare as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

A method of treating a disease selected from the group consisting of emphysema, sepsis, septic shock, ischemic injury, cerebral ischemia, a neurodegenerative disorder, meningitis, encephalitis, hemorrhage, cerebral ischemia, heart ischemia and a cognitive deficit in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a combination of at least two agents, wherein a first of said two agents upregulates an activity and/or expression of Nrf2 and a second of said two agents is a glutamatergic modulator, thereby treating the disease.

Combination treatment for amyotrophic lateral sclerosis (ALS)

An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence XXXXX, wherein Xis a hydrophobic amino acid or threonine, Xis a hydrophobic amino acid, Xis a hydrophobic amino acid, Xis an acidic amino acid and Xis selected from the group consisting of glycine, serine and alanine, the peptide capable of specifically inhibiting the activity of caspase 6.

Peptides for the treatment of neurodegenerative diseases

The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.

Stem cell-derived neural cells for cell therapy in neurological disorders

Growing community of inventors

Kfar HaRoe, Israel

Daniel Offen